Related Experiment Video

Updated: Jan 11, 2026

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis-Maternal Health Service: A

Rebecca Scott^1,2, Amy Downes^2,3, Ladina Weitnauer³

¹Department for Obstetric Medicine, Chelsea and Westminster Hospital, London, UK.

BJOG : an International Journal of Obstetrics and Gynaecology

|November 10, 2025

Abstract

Objective:

A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF-Maternal Health service.

Design:

Retrospective data review from a CF-Maternal Health service between September 2020 and February 2025.

Setting:

A large adult-CF service in London, UK.

Population Or Sample:

Pregnant fwCF attending the Royal Brompton Hospital CF Service.

Methods:

Review of CF-Maternal Health service data.

Main Outcome Measures:

Maternal, obstetric and neonatal outcomes.

Results:

Fifty-three fwCF completed 67 pregnancies, with 69 infants born. There were no stillbirths, neonatal or maternal deaths. ETI-therapy was reported in 81% of pregnancies. In fwCF without CF-Diabetes, 57% developed gestational diabetes. Hospital admission to treat an infective pulmonary exacerbation was required in 31% of pregnancies. Forty-five percent of pregnancies delivered vaginally; 78% of babies were born at term. A major congenital abnormality was diagnosed in 4% of infants. Baseline lung-function correlated positively with birth-weight and gestation at birth.

Conclusions:

FwCF have improved maternal, obstetric and neonatal outcomes since the introduction of ETI-therapy, within a dedicated CF-Maternal Health service.

Keywords:

CFTR‐modulators Elexacaftor/Tezacaftor/Ivacaftor cystic fibrosis maternal medicine pregnancy

More Related Videos

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Concept Videos

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Articles linked to this work by shared authors, journal, and citation graph.

Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.

BMJ open respiratory research·2026

International Delphi consensus recommendations for the follow-up of children born to people with CF and exposed to CFTR modulators in utero or through breastfeeding; endorsed by the European Cystic Fibrosis Society.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026

High Incidence of Gestational Diabetes Mellitus in Females With Cystic Fibrosis Persists in the Triple Cystic Fibrosis Transmembrane Conductance Regulator Modulator Era: Implications for Screening.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Noncoding DNA Variants Increase the Genetic Diagnostic Yield in Primary Ciliary Dyskinesia.

American journal of respiratory and critical care medicine·2025

Salt warning labels in the out-of-home food sector: online and real-world randomised controlled trials in the UK.

The Lancet. Public health·2025

Practice Readiness of Chief Residents in a National Sample During the First Year of EPA Assessments.

Annals of surgery·2025

See all related articles